HLB Life Science Co., Ltd.

A067630

KR7067630004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
16,950 ^KRW	-3.03%		+1.19%	+48.03%

Mar. 22	HLB Life Science to Raise 148.5 Billion Won via Shares Issuance; Shares Decline 8%	MT
Mar. 21	HLB Life Science Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

HLB Life Science Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021

March 23, 2022 at 03:45 am EDT

HLB Life Science Co., Ltd. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was KRW 666.25 million compared to KRW 346.08 million a year ago. Net loss was KRW 49,151.66 million compared to KRW 55,796.88 million a year ago.

Basic loss per share from continuing operations was KRW 494.4312 compared to KRW 563.8418 a year ago. Diluted loss per share from continuing operations was KRW 494.4312 compared to KRW 563.8418 a year ago. Basic loss per share was KRW 494.4312 compared to KRW 563.8418 a year ago.

Latest news about HLB Life Science Co., Ltd.

HLB Life Science to Raise 148.5 Billion Won via Shares Issuance; Shares Decline 8%	Mar. 22	MT
HLB Life Science Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
HLB Life Science Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
HLB Life Science Co., Ltd. announced that it has received KRW 28.799996266 billion in funding	Nov. 06	CI
HLB SCIENCE Inc. announced that it has received KRW 6.000000045 billion in funding from HLB Life Science Co., Ltd.	23-09-25	CI
HLB SCIENCE Inc. announced that it expects to receive KRW 6.000000045 billion in funding from HLB Life Science Co., Ltd.	23-09-17	CI
HLB Life Science Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
HLB Life Science Co., Ltd. announced that it has received KRW 8.3 billion in funding from HLB Therapeutics Co.,Ltd.	23-07-06	CI
HLB Life Science Co., Ltd. announced that it expects to receive KRW 8.3 billion in funding from HLB Therapeutics Co.,Ltd.	23-06-28	CI
HLB Life Science Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors	23-03-12	CI
HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors	23-01-31	CI
HLB Life Science Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
HLB Life Science Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
HLB Life Science Co., Ltd. announced that it has received KRW 45 billion in funding	22-06-30	CI
HLB Life Science Co., Ltd. announced that it expects to receive KRW 45 billion in funding	22-05-30	CI
HLB Life Science Co., Ltd. agreed to acquire AIM Inc from Yong Ho Cho and others for KRW 101,900 million.	22-05-30	CI
HLB Life Science Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
HLB Life Science Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
HLB Life Science Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Semisysco Co., Ltd announced that it has received KRW 26.960273555 billion in funding from HLB Life Science Co., Ltd.	21-08-31	CI
Semisysco Co., Ltd. announced that it expects to receive KRW 46.95914602 billion in funding from HLB Life Science Co., Ltd., and other investors	21-05-30	CI
HLB Life Science Co., Ltd. cancelled the acquisition of 14% stake in HLB Co., Ltd. from Jinyanggon, Hyuna Lee, Hyunsoo Lee, Alex S. Kim, Yongwoong Kim and Coughing season.	20-11-04	CI
HLB Life Science Co., Ltd. cancelled the acquisition of Geo Rim Co., Ltd.	20-03-31	CI
HLB Life Science Co., Ltd. completed the acquisition of an additional 8.85% stake in LSK BioPartners, Inc.	19-11-26	CI

Chart HLB Life Science Co., Ltd.

Duration

Period

More charts

Company Profile

HLB Life Science Co., Ltd. is a Korea-based company mainly engaged in the sale of pharmaceuticals. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. It is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
HLB LIFE SCIENCE CO., LTD.	+48.03%	1.32B
MCKESSON CORPORATION	+17.35%	71.39B
CARDINAL HEALTH, INC.	+2.39%	25.1B
SINOPHARM GROUP CO. LTD.	+5.38%	8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.69%	8.19B
HUADONG MEDICINE CO., LTD	-20.96%	7.91B
H. LUNDBECK A/S	+0.49%	4.54B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+17.12%	4.31B
EBOS GROUP LIMITED	-3.38%	3.93B
GALENICA AG	-2.61%	3.86B